This novel medical device is currently being evaluated in a multicenter clinical study in the European Union, assessing the safety and performance in patients with blepharitis. The multicentric clinical trial includes patients with mild to moderate blepharitis irrespective of root cause of the disease.
Perfluorohexyloctane + Omega-3 ophthalmic solution is being developed with the goal of providing patients with blepharitis a new effective treatment option to treat their signs and symptoms (EUDAMED: CIV-25-09-054318).
